Arbutus Biopharma Logo
Arbutus Settles Litigation, Terminating Acuitas’ Rights to LNP Technology
February 22, 2018 16:35 ET | Arbutus Biopharma Corporation
Acuitas has No Further Rights to Use or Sublicense Arbutus LNP TechnologyArbutus Consolidates LNP Patent Estate Enabling RNAi, mRNA, and Gene-editing Therapeutics VANCOUVER, B.C. and WARMINSTER, Pa.,...
Seelos_full logo and icon color.jpg
Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™
February 16, 2018 07:00 ET | Apricus Biosciences, Inc.
SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the...
Arbutus Biopharma Logo
Arbutus Enters Exclusivity Agreement with Roivant Sciences
February 14, 2018 20:50 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Biopharma Logo
Arbutus’ LNP Licensee Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Patisiran
November 16, 2017 13:40 ET | Arbutus Biopharma Corporation
VANCOUVER, B.C. and WARMINSTER, Pa., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company,...
Arbutus Biopharma Logo
Arbutus’ LNP Licensee Alnylam Receives Accelerated Assessment of Patisiran from European Medicines Agency (EMA)
November 13, 2017 17:22 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
Arbutus Biopharma Logo
Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results
November 02, 2017 16:00 ET | Arbutus Biopharma Corporation
Strategic Investment from Roivant Extends Cash RunwayCombination Study for ARB-1467 Starting in 4Q17Company to Host a Corporate Update Conference Call Today at 4:15 PM ET VANCOUVER, British Columbia...
Arbutus Biopharma Logo
Arbutus Announces Conference Call to Provide a Corporate Update and Third Quarter 2017 Financial Results
October 31, 2017 18:16 ET | Arbutus Biopharma Corporation
VANCOUVER, British Columbia and WARMINSTER, Pa., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions...
download-2.png
Emerald Health’s Two Cannabis Production Expansion Sites Progressing for Legalized Adult-Use Market in 2018
October 18, 2017 07:00 ET | Emerald Health Therapeutics Inc.
VICTORIA, British Columbia, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Emerald Health Therapeutics Inc. (“EHT”) (TSXV:EMH) (OTCQX:EMHTF), through Emerald Health Botanicals Inc. ("Emerald"), its wholly owned...
red.jpg
RedHill Biopharma Announces U.S. Commercialization Agreement for FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules
August 17, 2017 07:00 ET | RedHill Biopharma Ltd.
RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories          Esomeprazole Strontium DR...
Monsanto and ToolGen Announce Global Licensing Agreement on CRISPR Platform, Underscore the Benefits of Innovation for Farmers
August 16, 2017 08:30 ET | Toolgen, Inc.
ST. LOUIS and SEOUL, South Korea, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Monsanto Company (NYSE:MON) and ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, announced...